High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia
Open Access
- 26 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (9), 2128-2133
- https://doi.org/10.1093/jac/dkt133
Abstract
Thrombocytopenia is sometimes observed during linezolid therapy. Here, we aimed to investigate the factors affecting linezolid-induced thrombocytopenia. A prospective observational study was performed between October 2009 and February 2011; 30 patients were included. Plasma linezolid trough concentrations were measured on days 3, 7 and 14 after initial drug administration. Platelet counts and haemoglobin levels were also monitored. Thrombocytopenia occurred in 17 patients (56.7%). Median linezolid trough concentrations on day 3 were significantly higher in patients with renal impairment (creatinine clearance P < 0.0001). Median linezolid trough concentrations on day 3 in patients who developed thrombocytopenia were also significantly higher than those in patients who did not (13.4 versus 4.3 mg/L, P < 0.0001). Development of thrombocytopenia occurred significantly more frequently in patients with linezolid trough concentration >7.5 mg/L (OR, 90.0; P < 0.0001) and renal impairment (OR, 39.0; P = 0.0002). The Kaplan–Meier plot showed that the median time from the initiation of therapy to development of thrombocytopenia was 11 days. Patients with renal impairment are more likely to have a high plasma linezolid concentration. In addition, a high plasma linezolid concentration and renal impairment significantly affected the development of linezolid-induced thrombocytopenia. Further studies are required to evaluate whether therapeutic drug monitoring-guided dosage adjustment of linezolid decreases the adverse effects while maintaining treatment efficacy in patients with renal dysfunction.Keywords
This publication has 42 references indexed in Scilit:
- The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolidCurrent Medical Research and Opinion, 2010
- Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapyClinical Therapeutics, 2009
- A comparison of linezolid with glycopeptides in severe MRSA pneumoniaExpert Review of Anti-infective Therapy, 2009
- Linezolid: a review of safety and tolerabilityJournal of Infection, 2009
- Pharmacologic options for CNS infections caused by resistant Gram-positive organismsExpert Review of Anti-infective Therapy, 2008
- Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case seriesDiagnostic Microbiology and Infectious Disease, 2007
- Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiencyInternational Journal of Antimicrobial Agents, 2006
- A review of linezolid: the first oxazolidinone antibiotic.Expert Review of Anti-infective Therapy, 2004
- Thrombocytopenia Associated with Linezolid TherapyClinical Infectious Diseases, 2002